Correction: Cost-Effectiveness of Statins in Older Patients with Myocardial Infarction
Authors: David A. Ganz, Karen M. Kuntz, Joshua S. Benner, Jerry Avorn
Journal: Annals of Internal Medicine (2002)

Letters16 April 2002Correction: Cost-Effectiveness of Statins in Older Patients with Myocardial InfarctionDavid A. Ganz, MD, MPH, Karen M. Kuntz, ScD, Joshua S. Benner, PharmD, ScD, and Jerry Avorn, MDDavid A. Ganz, MD, MPHUniversity of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn)Search for more papers by this author, Karen M. Kuntz, ScDUniversity of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn)Search for more papers by this author, Joshua S. Benner, PharmD, ScDUniversity of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn)Search for more papers by this author, and Jerry Avorn, MDUniversity of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-8-200204160-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:During further work with our model of the cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (“statin”) therapy in older patients with myocardial infarction (1), we discovered an error in one aspect of the model presented. This error does not change the paper's conclusion but alters some of the results presented. In Table 1 of the article, the base-case risk ratio for death from all causes other than myocardial infarction and stroke should be 1.03, not 1.52. Rerunning the model with this new base-case value results in mean undiscounted life expectancies of 6.78 and 7.40 years, respectively, for ...References1. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocar-dial infarction. Ann Intern Med. 2000;132:780-7. [PMID: 10819700] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of California, Los Angeles, Medical Center; Los Angeles, CA 90095 (Ganz)Harvard School of Public Health; Boston, MA 02115 (Kuntz)Brigham and Women's Hospital and Harvard Medical School; Boston, MA 02115 (Benner, Avorn) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction David A. Ganz , Karen M. Kuntz , Gretchen A. Jacobson , and Jerry Avorn Metrics Cited byImpediments to Adherence to Post Myocardial Infarction MedicationsAn economic evaluation of prolonged mechanical ventilation*A review of health care models for coronary heart disease interventions 16 April 2002Volume 136, Issue 8Page: 635KeywordsCoenzymesLife expectancyMyocardial infarctionQuality adjusted life expectancyRisk ratioStatins ePublished: 16 April 2002 Issue Published: 16 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...